05JUN

Welcome To Mediterr J Med Med Sci

 

Manuscripts should be addressed to Editor-in-Chief: http://medjpps.com/mjpps/Submission or to editor@medjpps.com / fmosherif@yahoo.com

Mediterranean Journal of Medicine and Medical Sciences
http://www.mjmmr.periodikos.com.br/article/doi/10.5281/zenodo.15713051

Mediterranean Journal of Medicine and Medical Sciences

REVIEW

Exploring Helicobacter pylori infection, diagnosis, and prospect

Md. Aktaruzzaman

Downloads: 2
Views: 246

Abstract

Helicobacter pylori is a gram-negative, short helical, S-shaped microbe that is 0.5-1 micrometer broad and 2-4 micrometer long. It causes chronic gastric infections and is primarily located in the pyloric area of the stomach. It is believed that almost half of the world's population is infected with these bacteria. Although the precise mechanism of Helicobacter pylori infection and transmission remains unknown, it is believed that the fecal-oral and oral-oral pathways, facilitated by food or water consumption, are prevalent. The pathogenicity, microbial activity, genetic predisposition, and clinical therapies of Helicobacter pylori-induced gastric atrophy and gastric cancer have garnered more attention in the past three decades. Research has indicated that Helicobacter pylori infection may influence the prevalence of malnutrition in specific risk groups and that it may be linked to the inability to absorb vital minerals. An adequate and balanced diet, particularly one that is high in fruits and vegetables and low in processed salty foods, has been shown to have a protective effect against the consequences of Helicobacter pylori infection. On the other hand, dietary factors may play a significant role in H. pylori infection. The current review offers a comprehensive summary of every facet of Helicobacter pylori infection, including advanced treatment and diagnosis.

Keywords

Antibiotic, gut, infection, peptic ulcer

References

  1. Hooi, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153(2): 420-429. doi: 10.1053/j.gastro.2017.04.022
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA; A Cancer Journal for Clinicians. 2018; 68(6): 394-424. doi: 10.3322/caac.21492
  3. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. The Lancet, Global Health. 2016; 4(9): e609-616. doi: 10.1016/S2214-109X(16)30143-7
  4. Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: A case-cohort study. The Lancet, Public Health. 2021; 6(12): e888-e896. doi: 10.1016/S2468-2667(21)00164-X
  5. Yang H, Yang WJ, Hu B. Gastric epithelial histology and precancerous conditions. World Journal of Gastrointestinal Oncology. 2022; 14(2): 396-412. doi: 10.4251/wjgo.v14.i2.396
  6. Yang H, Hu B. Immunological Perspective: Helicobacter pylori Infection and Gastritis. Mediators of Inflammation. 2022; 2022: 2944156. doi: 10.1155/2022/2944156
  7. Maubach G, Vieth M, Boccellato F, Naumann M. Helicobacter pylori-induced NF-κB: trailblazer for gastric pathophysiology. Trends in Molecular Medicine. 2022; 28(3): 210-222. doi: 10.1016/j.molmed.2021.12.005
  8. Lin M, Tu RH, Wu SZ, Zhong Q, Weng K, Wu YK, et al. Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway. Cell Death and Disease. 2024; 15(7): 497. doi: 10.1038/s41419-024-06885-2
  9. Wang J, Deng R, Chen S, Deng S, Hu Q, Xu B, et al. Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. iScience. 2023; 26(12): 108414. doi: 10.1016/j.isci. 2023.108414
  10. Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. The Cochrane Database of Systematic Review. 2020; 7(7): CD005583. doi: 10.1002/14651858. CD005583.pub3
  11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023-1075. do: doi: 10.1016/S0140-6736(17)33326-3
  12. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745
  13. Kira JI, Isobe N. Helicobacter pylori infection and demyelinating disease of the central nervous system. Journal of Neuroimmunology. 2019; 329: 14-19. do: Nil.
  14. Lee M, Baek H, Park JS, Kim S, Kyung C, Baik SJ. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One. 2018; 13(3): e0193646. doi: 10.1371/journal.pone.0193646
  15. Wang L, Chen J, Jiang W, Cen L, Pan J, Yu C, et al. The relationship between Helicobacter pylori infection of the gallbladder and chronic cholecystitis and cholelithiasis: A systematic review and meta-Analysis. Canadian Journal of Gastroenterology and Hepatology. 2021; 2021: 8886085. doi: 10.1155/2021/8886085
  16. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. Frontiers in Immunology. 2024; 15: 1339971. doi: 10.3389/fimmu.2024.1339971
  17. Lehours, P. Actual diagnosis of Helicobacter pylori infection. Minerva Gastroenterologica e. Dietologica. 2018, 64: 267-279. doi: 10.23736/S1121-421X.18.02494-7
  18. Vilaichone RK, Mahachai V, Shiota S, Uchida T, Ratanachu-ek T, Tshering L, et al. Extremely high prevalence of Helicobacter pylori infection in Bhutan. World Journal of Gastroenterology. 2013; 19(18): 2806-2810. doi: 10.3748/wjg.v19.i18.2806
  19. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017; 153(2): 420-429. doi: 10.1186/s12879-023-08504-5
  20. Mard SA, Khadem Haghighian H, Sebghatulahi V, Ahmadi B. Dietary factors in relation to Helicobacter pylori infection. Gastroenterology Research and Practice. 2014; 2014: 826910. doi: 10.1155/2014/826910
  21. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C. Prevalence of Helicobacter pylori and its associated factors among healthy asymptomatic residents in the United Arab Emirates. Pathogens. 2019; 8(2): 44. doi: 10.3390/pathogens8020044
  22. Mezmale L, Coelho LG, Bordin D, Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020; 25 Suppl 1: e12734. doi: 10.1111/hel.12734
  23. Ozen A, Furman A, Berber M, Karatepe HO, Mutlu N, Sarıçoban HE, Büyükgebiz B. The effect of Helicobacter pylori and economic status on growth parameters and leptin, ghrelin, and insulin-like growth factor (IGF)-I concentrations in children. Helicobacter. 2011; 16(1): 55-65. doi: 10.1111/j.1523-5378.2010.00814.x
  24. Lin SK, Lambert JR, Schembri MA, Nicholson L, Korman MG. Helicobacter pylori prevalence in endoscopy and medical staff. Journal of Gastroenterology and Hepatology. 1994; 9(4): 319-324. doi: 10.1111/j.1440-1746. 1994.tb01249.x
  25. Soylu A, Peker KD, Yırgın H, Polat S, et al. Evaluation of H. pylori and Histopathological findings in patients with dyspepsia. Journal of Medical Faculty Clinics 2019: 2(4): 139-141. doi: Nil.
  26. Mehata S, Parajuli KR, Pant ND, Rayamajhee B, Yadav UN, Mehta RK, et al. Prevalence and correlates of Helicobacter pylori infection among under-five children, adolescent and non-pregnant women in Nepal: Further analysis of Nepal national micronutrient status survey 2016. PLoS Neglected Tropical Disease. 2021; 15(6): e0009510. doi: 10.1371/journal.pntd.0009510
  27. Zamani M, Vahedi A, Maghdouri Z, Shokri-Shirvani J. Role of food in environmental transmission of Helicobacter pylori. Caspian Journal of Internal Medicine. 2017; 8(3): 146-152. doi: 10.22088/cjim.8.3.146
  28. Vale FF, Vítor JM. Transmission pathway of Helicobacter pylori: Does food play a role in rural and urban areas? Internal Journal of Food Microbiology. 2010; 138(1-2): 1-12. doi: 10.1016/j.ijfoodmicro.2010.01.016
  29. Zhang YY, Xia HH, Zhuang ZH, Zhong J. Review article: 'true' re-infection of Helicobacter pylori after successful eradication-worldwide annual rates, risk factors and clinical implications. Alimentary Pharmacology and Therapeutics. 2009; 29(2): 145-60. doi: 10.1111/j.1365-2036.2008.03873.x
  30. Goodman KJ, Correa P, Tenganá Aux HJ, Ramírez H, DeLany JP, Guerrero Pepinosa O, et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. American Journal of Epidemiology. 1996; 144(3): 290-299. doi: 10.1093/oxfordjournals.aje.a008924
  31. Rafi IK (2025) Natural treatment for nausea and vomiting: A short message. Mediterranean Journal of Medical Research. 2: 32-37. doi: 10.5281/zenodo.15427363
  32. Nisha KJ, Nandakumar K, Shenoy KT, Janam P. Periodontal disease and Helicobacter pylori infection: A community-based study using serology and rapid urease test. Journal of Investigative and Clinical Dentistry. 2016; 7(1): 37-45. doi: 10.1111/jicd.12122
  33. Aksit Bıcak D, Akyuz S, Kıratlı B, Usta M, Urganci N, Alev B, Yarat A, Sahin F. The investigation of Helicobacter pylori in the dental biofilm and saliva samples of children with dyspeptic complaints. BMC Oral Health. 2017; 17(1): 67. doi: doi: 10.1186/s12903-017-0361-x
  34. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011;16 Suppl 1(0 1): 1-9. doi: 10.1111/j.1523-5378.2011.00874.x
  35. Dore MP, Pes GM. What is new in Helicobacter pylori diagnosis: An overview. Journal of Clinical Medicine. 2021; 10(10): 2091. doi: 10.3390/jcm10102091
  36. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. American Journal of Surgery and Pathology. 1996; 20(10): 1161-1181. doi: 10.1097/00000478-199610000-00001
  37. Glickman JN, Noffsinger A, Nevin DT, Ray M, Lash RH, Genta RM. Helicobacter infections with rare bacteria or minimal gastritis: Expecting the unexpected. Digestive and Liver Disease. 2015; 47(7): 549-555. doi: 10.1016/j.dld.2015.04.005
  38. Lash RH, Genta RM. Routine anti-Helicobacter immunohistochemical staining is significantly superior to reflex staining protocols for the detection of Helicobacter in gastric biopsy specimens. Helicobacter. 2016; 21(6): 581-585. doi: 10.1111/hel.12315
  39. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6-30. doi: 10.1136 /gutjnl-2016-312288
  40. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol. 2018; 16(7): 992-1002.e6. doi: 10.1016/j.cgh.2018.03.013
  41. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. American Journal of Gastroenterology. 2006; 101(8): 1921-1930. doi: 10.1111/j.1572-0241.2006.00668.x
  42. Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. American Journal of Medicine. 2019; 132(4): 447-456. doi: 10.1016/j.amjmed.2018.12.009
  43. Rafi IK, Aktaruzzaman Md (2025) Lifestyle and nutritional deficiencies associated with vegetarian diets. Mediterranean Journal of Medical Research. 02: 20-25. doi: 10.5281/zenodo.15336103
  44. Ramakrishnan K, Salinas RC. Peptic ulcer disease. American Family Physician. 2007; 76(7): 1005-1012. PMID: 17956071.
  45. Yeo SH, Yang CH. Peptic ulcer disease associated with helicobacter pylori infection. Korean Journal of Gastroenterology. 2016; 67(6): 289-299. doi: 10.4166/kjg.2016.67.6.289
  46. Wong CS, Chia CF, Lee HC, Wei PL, Ma HP, Tsai SH, Wu CH, Tam KW. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. Journal of Surgery and Research. 2013; 182(2): 219-226. doi: 10.1016/j.jss.2012.10.046
  47. Seo SI, Kim SJ, Kim HS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY. Is there any difference in the eradication rate of Helicobacter pylori infection according to the endoscopic stage of peptic ulcer disease? Helicobacter. 2015; 20(6): 424-430. doi: 10.1111/hel.12221
  48. Jinling X, Guoan L, Chuxi C, Qiaoyuan L, Yinzhong C, Shihao C, et al. NOTCH1 is positively correlated with IL17F in Helicobacter pylori infection and a biomarker for mucosal injury. iScience. 2024; 27(7): 110323. doi: 10.1016/j.isci.2024.110323
  49. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. American Journal of Gastroenterology. 2017; 112(2): 212-239. doi: 10.1038/s41395-018-0132-6
  50. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al. European registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut. 2021; 70(1): 40-54. doi: 10.1136/gutjnl-2020-321372
  51. Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022; 103(1): 62-68. doi: 10.1159/000519413
  52. Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018; 23(2): e12475. doi: 10.1111/hel.12475
  53. Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, et al. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut and Liver. 2021; 15(2): 168-195. doi: 10.5009/gnl20288
  54. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019; 24(4): e12597. doi: 10.1111/ hel.12597
  55. Lee YC, Dore MP, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. Annual Review of Medicine. 2022; 73: 183-195. doi: 10.1146/annurev-med-042220-020814
  56. Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Helicobacter. 2020; 25(6): e12762. doi: 10.1111/hel.12762
  57. Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and cost-effectiveness comparison of 10-day, 14-day sequential versus 14-day triple therapies for treating Helicobacter pylori infection in Egyptian patients. Journal of Clinical Gastroenterology. 2020; 54(9): 806-812. doi: 10.1097/MCG.0000000000001278
  58. Hsu PI, Tsay FW, Kao JY, Peng NJ, Tsai KW, Tsai TJ, et al. Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology. 2020; 35(10): 1731-1737. doi: doi: 10.1111/jgh.15034
  59. Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, et al. 10-day versus 14-day quadruple concomitant nonbismuth therapy for the treatment of Helicobacter pylori infection: Results from a randomized prospective study in a high clarithromycin resistance country. Journal of Clinical Gastroenterology. 2020; 54(6): 522-527. doi: 10.1097/MCG.0000000000001328
  60. Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterology. 2021; 21(1): 95. doi: 10.1186/s12876-021-01680-1
  61. Graham DY. Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (Basel). 2020; 9(10): 671. doi: 10.3390/antibiotics9100671
  62. Kaptchuk TJ, Shaw J, Kerr CE, Conboy LA, Kelley JM, Csordas TJ, Lembo AJ, Jacobson EE. Maybe I made up the whole thing: placebos and patients' experiences in a randomized controlled trial. Culture, Medicine, and Psychiatry. 2009; 33(3): 382-411. doi: 10.1007/s11013-009-9141-7

Submitted date:
05/19/2025

Reviewed date:
06/20/2025

Accepted date:
06/21/2025

68571defa953957e570f8dfb mjmmr Articles
Links & Downloads

Mediterr J Med Med Sci

Share this page
Page Sections